Jonathan Rios-Doria Email & Phone Number

Wilmington, De, Us

Wilmington, Delaware, United States

• Serve as project lead for monoclonal and bispecific antibody Discovery projects• Direct in vivo pharmacology plan for 6 preclinical antibody projects, including bispecific and monoclonal antibodies in the Biotherapeutics portfolio. • Advise management and champion technology development aligned with company strategy to feed early pipeline• Manage and supervise highly skilled research associates• Work with CROs to complete time-sensitive studies to support pipeline progression• Discovery Biology lead for clinical oral PD-L1 programs INCB099280 and INCB099318• Chair global in vivo pharmacology meetings across Incyte’s Biotherapeutics and small molecule pharmacology teams

Wilmingtom, Delaware

• Directed IND-enabling in vivo pharmacology studies and serve as biology lead for INCB081776, asmall molecule dual inhibitor of AXL and MER kinases, which is currently in Phase I clinical trials• Designed IND-enabling in vivo pharmacology studies for 3 oral small molecule inhibitors of PD-L1(INCB086550, INCB099280 and INCB099318), which are currently in clinical trials.• Served as project lead for an IO project and supported in vivo pharmacology for several small molecule Discovery projects• Demonstrated ability to work cross-functionally and collaboratively• Support target validation and strategic business development initiatives• Hired, managed and mentored team of 6 pharmacology associates including PhD-level scientists• Lead studies to identify MOA, efficacy, PK/PD and design studies to support patient selection• Developed internal humanized mouse platform at Incyte to evaluate small molecules and biologics forIO therapy and combinations• Manage external collaborations and CRO studies

Gaithersburg, Md

• Lead in vivo ADC and immunotherapy combination studies in syngeneic mouse models for multiple programs• Co-lead target validation for multi-specific immuno-oncology drugs using novel technology platforms• Serve as in vivo pharmacology lead for cancer stem cell antibody therapeutic programs• Supported in vivo pharmacology and milestone transitions for MEDI9447, an antibody to CD73, which is now in Phase I clinical trials• Manage team of pharmacology associates and provide mentorship, development and career guidance for associates• Manage multiple complex research projects, external collaborations, and CRO studies

Gaithersburg, Md

• Manage in vivo pharmacology team of three and provide mentorship, development, and career guidance for associates • Generated high-quality and high-impact in vivo efficacy, MOA, PK/PD and in vitro data that strongly influenced pipeline progression and achieved critical milestones• Utilized xenograft, PDX and syngeneic cancer models for evaluating activity of monoclonal antibodies, antibody drug conjugates and immune-mediated therapies for cancer • Work effectively in matrix environment to achieve program goals and collaborate frequently both within and outside of the department• Co-led innovative idea that placed in the top 5 in an organization-wide (including AstraZeneca) competition for innovative ideas•Manage external collaborations and projects with CROs

Tampa, Fl

• Manage preclinical study planning and execution and write final report documents for FDA and collaborator distribution.• Manage in vitro study projects to support efficient and timely in vivo project completion.• Write patents, grants, and contract proposals

• Established Intezyne’s tissue culture research laboratory from the ground up in a new facility, directed laboratory design and acquired equipment and instrumentation.• Lead preclinical development of multiple drug-loaded nanoparticles in Intezyne’s pipeline that include formulations of daunorubucin, SN-38, and paclitaxel.• Supervise, train and mentor biological staff members.• Develop novel analytical methods/in vitro assays to characterize nanoparticles and translate them into animal studies such as pharmacokinetic, biodistribution, and xenograft experiments.• Utilized pharmacodynamic markers for anticancer drug-loaded nanoparticle activity in cancer cells to validate nanoparticle delivery.• Guided experimental design that generated valuable preclinical data which directly attracted >$1 million in financial investments in the company.• Led siRNA delivery project that resulted in the development of effective siRNA-loaded nanoparticles to be delivered to cancer cells.• Led research project identifying cancer stem cells in an engineered cell line resistant to topoisomerase I inhibitors.• Manage biological laboratory operations including budgeting and administration, instrument maintenance, and enforcing lab safety protocols.• Created over 30 SOPs for the biological laboratory that resulted in increased productivity for biological staff members.• Wrote a grant proposal that was funded by SAIC-Frederick

• Generated stable Histone GFP-expressing HeLa cells with over 90% GFP positive.• Developed a novel three-color flow cytometric assay for detection of mitosis and apoptosis in GFP-transfected cells.• Employed shRNA against proteins in DNA damage pathway to sensitize cancer cells to radiation-induced apoptosis.

• First to identify E-cadherin and Beta-catenin as substrates of calpain protease in prostate and mammary epithelial cells.• Identified E-cadherin and Beta-catenin proteolytic cleavage products as potential cancer biomarkers in prostate and mammary tumors.

Ph.D., Cellular And Molecular Biology

B.S., Cellular And Molecular Biology